Home \ Pharmacology and biochemistry \ Known and new ideas about the mechanism of action and spectrum of effects of Mexidol

Known and new ideas about the mechanism of action and spectrum of effects of Mexidol

Author:
© T.A. VORONINA1, S.A. LITVINOVA1, N.A. GLADYSHEVA1, A.V. SHULYNDIN2

1Federal Research Center for Original and Promising Biomedical and Pharmaceutical
Technologies, Moscow, Russia;
2Volga Region Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, v. 125, no. 5, pp. 22–33

Abstract: The article
presents the results of studies of the multimodal mechanism of action of the domestic original drug Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate), which provides a neuroprotective effect and a wide range of clinical effects. The Mexidol molecule is represented by two related and functionally significant components: 2-ethyl-6-methyl-3 hydroxypyridine and succinate. The presence of 3-hydroxypyridine in the structure of Mexidol is associated with the antioxidant and membranotropic activity of the drug, the ability to reduce glutamate excitotoxicity, modulate the functioning of receptors and ion channels. Succinate in Mexidol provides the ability to induce the succinate receptor SUCNR1, improve succinate signaling, stimulate mitochondriogenesis, restore mitochondrial respiration and activate the Krebs cycle, increase the energy status of the cell, which causes the antihypoxic effect. Mexidol enhances the expression of transcription factors HIF-1α, Nrf2 under hypoxic conditions, has neuroregenerative activity mediated by an increase in the levels of the main regulatory molecules - neurotrophic factors NGF, IGF1, BDNF and VEGF in areas of ischemic brain damage, and also has a positive effect on PGC-1α, coordinating aerobic metabolism and energy stability of cells. These features distinguish Mexidol from other succinic acid preparations.

Key words: Mexidol, ethylmethylhydroxypyridine succinate, antioxidant, antihypoxant, neuroprotection,
mitochondriogenesis, succinate signaling, neurotrophic factors, transcription factors.

Read more to the library

Actual

Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Reproduced drugs: Benefit ratio/risk
Reproduced drugs: Benefit ratio/risk
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
Arterial hypertension and cognitive disorders. The gaze of a neurologist
Arterial hypertension and cognitive disorders. The gaze of a neurologist
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemispherical ischemic stroke (the results of subanalysis of a randomized double blind multicenter placebo-controlled epic study)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemispherical ischemic stroke (the results of subanalysis of a randomized double blind multicenter placebo-controlled epic study)
Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here
Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here

Actual

Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Cognitive disorders in the practice of a primary link: Focus for patients with arterial hypertension
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
Resolution of the Council of Experts "The possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders"
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Reproduced drugs: Benefit ratio/risk
Reproduced drugs: Benefit ratio/risk
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
Treatment of patients with ischemic stroke in the vertebral-baslar system in the acute period: Experience in the use of the neuroprotective drug Mexidol
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The use of Mexidol in patients with mild (moderate) cognitive disorders: the results of meta -analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis
Arterial hypertension and cognitive disorders. The gaze of a neurologist
Arterial hypertension and cognitive disorders. The gaze of a neurologist
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemisphere ischemic stroke (the results of subanarized a randomized double blind multicenter placebo-controlled in parallel groups of the study of epic)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemispherical ischemic stroke (the results of subanalysis of a randomized double blind multicenter placebo-controlled epic study)
The effectiveness and safety of Mexidol in patients of different age groups in the acute and early recovery periods of the hemispherical ischemic stroke (the results of subanalysis of a randomized double blind multicenter placebo-controlled epic study)
Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here
Results of a multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of Mexidol in the treatment of attention deficit hyperactivity disorder in children (MEGA) Link to study status here

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com